ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Immune phenotype and RAS/BRAF status predict outcomes after lung metastasectomy for colorectal cancer.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Outcomes following different thermal ablation strategies in patients with oligometastatic colorectal lung metastases.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeColorectal cancer (CRC) presents a marked biological heterogeneity, and the lung is a frequent site of metastatic spread. Although pulmonary metastasectomy can lead to a long-term survival, recurrence rates remain high and prognostic markers are lacking. This study evaluated the prognostic value of clinical, molecular, and histopathological features in CRC patients undergoing lung metastasectomy.
methodsA retrospective cohort of CRC patients who underwent pulmonary metastasectomy at Hospital de la Santa Creu i Sant Pau between September 2011 and October 2023 was analyzed. Clinical variables, molecular alterations, and histopathological characteristics were collected. Immune phenotype (IP) and histological growth pattern (HGP) were assessed by pathologists and survival outcomes were estimated using Kaplan-Meier methods.
results61 patients (median age 67 years) were included. Median overall survival (OS) was 73.1 months, and median recurrence-free survival (RFS) was 17.5 months. Early-stage CRC at diagnosis (stages I-II) was associated with longer RFS (42.7 vs 12.6 months; p = 0.02), whereas elevated preoperative CEA levels predicted shorter RFS (7.1 vs. 21.3 months, p = 0.005) and lung-only metastatic disease was associated with longer OS (80.3 vs 28.6 months; p = 0.01). An immune-desert IP correlated with shorter RFS (4.0 vs. 20.4 months, p = 0.03), and tumors harboring RAS/BRAF mutations had worse lung-specific RFS (14.9 vs. 24.3 months, p = 0.034).
conclusionsAn immune-desert phenotype and RAS/BRAF mutations identify CRC patients at higher risk of recurrence after lung metastasectomy, whereas earlier CRC stage and solitary lung metastasis are associated with more favorable outcomes. Integrating clinical, molecular, and immune-histologic features may improve selection for pulmonary metastasectomy in oligometastatic CRC.
Indexed as
Identifiers
41963636What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.